
It will not need to recontact these individuals for consent because their original consent agreements cover whole genome sequencing, Stefansson says.

To further its search for disease genes, the company plans to begin whole genome sequencing of 2500 DNA samples from its database. "We cannot provide people unfettered access to the data," Stefansson says. Stefansson says this does not raise privacy concerns because Iceland's data privacy and ethics laws will only permit deCODE to "work on problems" for the companies. It will partner with drug companies instead of developing drugs on its own from its gene discoveries, Collier says. "The plan is to continue to lead the world when it comes to human genetics," says Stefansson. The new deCODE will still focus on human genetics, including selling diagnostic tests and a personal genome analysis service, deCODEme.

The parent company is still selling off deCODE genetics Inc.'s drug discovery and development components, says Stefansson. The CEO of the new private company, called deCODE genetics ehf, is Earl "Duke" Collier, a former executive vice president at Genzyme Stefansson will be executive chairman and president of research. Saga's investors include two firms that invested in the original deCODE as well as Illumina, the sequencing machine company in San Diego, California. Last week, a bankruptcy court in Delaware approved the sale of deCODE Inc.'s subsidiary Islensk Erfdagreining, which runs this biobank, to Saga Investments LLC. hasn't turned a profit, but it has made a scientific splash by finding disease risk markers using a genetic, medical, and genealogical database on 140,000 Icelanders. Over the past decade deCODE genetics Inc. deCODE's founder, neuroscientist Kari Stefansson, is staying on as co-leader. Today it reappeared as "the New deCODE," a renamed version of the previous deCODE's core business built on mining the DNA of Iceland's population for disease-causing genes.

DeCODE genetics, the Icelandic genomics company that declared bankruptcy in November, has made a comeback.
